IT20.F Aclarion, Inc.

Healthcare Health Information Services Frankfurt Exchange
1.19 EUR
Close of Nov 12, 2026
1.18 7.92
Market cap
EUR 3.43M
P/E
-
P/B
0.25x
ROE
-74.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IT20.F undervalued?

Graham number

The Graham number of Aclarion, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aclarion, Inc. fundamental analysis

No fundamental analysis for Aclarion, Inc. yet.

Aclarion, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aclarion, Inc.

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequen…

Full company profile